AbbVie SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 30, 2026, 7:51 a.m. ETView on SEC.gov Our explainer
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedAbbVie Q3 2026 adjusted EPS $3.82 beats $3.77 consensus on $17.404 billion revenue; full-year adjusted EPS guidance raised to $13.95-$13.99
8-KOct. 15, 2026, 4 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
8-KOct. 5, 2026, 4:07 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
4Oct. 2, 2026, 5 p.m. ETView on SEC.gov
4Oct. 2, 2026, 5 p.m. ETView on SEC.gov
8-KSept. 3, 2026, 8:47 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
4Aug. 18, 2026, 5 p.m. ETView on SEC.gov
8-KAug. 18, 2026, 4:30 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
424B5Aug. 6, 2026, 5:08 p.m. ETView on SEC.gov
8-KAug. 5, 2026, 5:17 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
424B5Aug. 4, 2026, 8:18 a.m. ETView on SEC.gov
10-QAug. 3, 2026, 2:14 p.m. ETView on SEC.gov
8-KJuly 31, 2026, 7:51 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits